Lack of association between TRAF1/C5 gene polymorphisms and biopsy-proven giant cell arteritis

Journal of Rheumatology

Volumn 37, Issue 1, 2010, Pages 131-135

  Torres, Orlando ^a   Palomino Morales, Rogelio ^a   Vazquez Rodriguez, Tomas R ^b   Castañeda, Santos ^c   Morado, Inmaculada C ^d   Miranda Filloy, Jose A ^b   Ortego Centeno, Norberto ^e   Gonzalez Alvaro, Isidoro ^c   Fernandez Gutierrez, Benjamin ^d   Martin, Javier ^a   Gonzalez Gay, Miguel A ^b  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^b HOSPITAL XERAL CALDE   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

Author keywords

Disease susceptibility; Gene polymorphism; Genetic studies; Giant cell arteritis; TRAF1 C5 gene

Indexed keywords

COMPLEMENT COMPONENT C5; CORTICOSTEROID; DNA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1;

ADULT; AGED; ALLELE; ARTICLE; BLOOD SAMPLING; BLOOD VESSEL BIOPSY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE PREDISPOSITION; FEMALE; GENETIC ASSOCIATION; GENOTYPE; GIANT CELL ARTERITIS; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AGED, 80 AND OVER; BIOPSY; COMPLEMENT C5; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GIANT CELL ARTERITIS; HUMANS; MIDDLE AGED; POLYMORPHISM, GENETIC; TNF RECEPTOR-ASSOCIATED FACTOR 1;

EID: 73649119522     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090646     Document Type: Article

References (28)

1. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, Miranda-Filloy JA, Gonzalez-Juanatey C, Martin J, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 2009;61:1454-61.
2. Weyand CM, Goronzy JJ. Arterial wall injury in giant cell arteritis. Arthritis Rheum 1999;42:844-53.
3. Gonzalez-Gay MA, Amoli MM, Garcia-Porrua C, Ollier WE. Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin Arthritis Rheum 2003;33:38-48.
4. Rueda B, Lopez-Nevot MA, Lopez-Diaz MJ, Garcia-Porrua C, Martín J, Gonzalez-Gay MA. A functional variant of vascular endothelial growth factor is associated with severe ischemic complications in giant cell arteritis. J Rheumatol 2005;32:1737-41.
5. Gonzalez-Gay MA, Hajeer AH, Dababneh A, Garcia-Porrua C, Amoli MM, Llorca J, et al. Interferon-gamma gene microsatellite polymorphisms in patients with biopsy-proven giant cell arteritis and isolated polymyalgia rheumatica. Clin Exp Rheumatol 2004;22 Suppl:S18-20.
6. Rodriguez-Pla A, Beaty TH, Savino PJ, Eagle RC Jr, Seo P, Soloski MJ. Association of a nonsynonymous single-nucleotide polymorphism of matrix metalloproteinase 9 with giant cell arteritis. Arthritis Rheum 2008;58:1849-53.
7. Palomino-Morales R, Torres O, Vazquez-Rodriguez TR, Morado IC, Castañeda S, Callejas-Rubio JL, et al. Association between toll-like receptor 4 gene polymorphism and biopsy-proven giant cell arteritis. J Rheumatol 2009;36:1501-6.
8. Orozco G, Rueda B, Martin J. Genetic basis of rheumatoid arthritis. Biomed Pharmacother 2006;60:656-62.
9. Dababneh A, Gonzalez-Gay MA, Garcia-Porrua C, Hajeer A, Thomson W, Ollier W. Giant cell arteritis and polymyalgia rheumatica can be differentiated by distinct patterns of HLA class II association. J Rheumatol 1998;25:2140-5.
10. Mattey DL, Hajeer AH, Dababneh A, Thomson W, Gonzalez-Gay MA, Garcia-Porrua C, et al. Association of giant cell arteritis and polymyalgia rheumatica with different tumor necrosis factor microsatellite polymorphisms. Arthritis Rheum 2000;43:1749-55.
11. Gonzalez-Gay MA, Hajeer AH, Dababneh A, Garcia-Porrua C, Mattey DL, Amoli MM, et al. IL-6 promoter polymorphism at position -174 modulates the phenotypic expression of polymyalgia rheumatica in biopsy-proven giant cell arteritis. Clin Exp Rheumatol 2002;20:179-84.
12. Plenge RM, Seielstad M, Padyukov L, Lee AT, Remmers EF, Ding B, et al. TRAF1-C5 as a risk locus for rheumatoid arthritis - a genomewide study. N Engl J Med 2007;357:1199-209.
13. Kurreeman FA, Padyukov L, Marques RB, Schrodi SJ, Seddighzadeh M, Stoeken-Rijsbergen G, et al. A candidate gene approach identifies the TRAF1/C5 region as a risk factor for rheumatoid arthritis. PLoS Med 2007;4:e278. Erratum in: PLoS Med 2007;4:e358.
14. Tsitsikov EN, Laouini D, Dunn IF, Sannikova TY, Davidson L, Alt FW, et al. TRAF1 is a negative regulator of TNF signaling. Enhanced TNF signaling in TRAF1-deficient mice. Immunity 2001;15:647-57.
15. Schmidt RE, Gessner JE. Fc receptors and their interaction with complement in autoimmunity. Immunol Lett 2005;100:56-67.
16. Knecht S, Henningsen H, Rauterberg EW. Immunohistology of temporal arteritis: phenotyping of infiltrating cells and deposits of complement components. J Neurol 1991;238:181-2.
17. Hernandez-Rodriguez J, Segarra M, Vilardell C, Sanchez M, Garcia-Martinez A, Esteban MJ, et al. Tissue production of pro-inflammatory cytokines (IL-1 beta, TNF alpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology 2004;43:294-301.
18. Barton A, Thomson W, Ke X, Eyre S, Hinks A, Bowes J, et al. Re-evaluation of putative rheumatoid arthritis susceptibility genes in the post-genome wide association study era and hypothesis of a key pathway underlying susceptibility. Hum Mol Genet 2008;17:2274-9.
19. Kurreeman FA, Goulielmos GN, Alizadeh BZ, Rueda B, Houwing-Duistermaat J, Sánchez E, et al. The TRAF1-C5 region on chromosome 9q33 is associated with multiple autoimmune diseases. Ann Rheum Dis 2009 May 18. [Epub ahead of print]
20. Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, Gonzalez-Louzao C, Rodriguez-Ledo P. Biopsy-negative giant cell arteritis: clinical spectrum and predictive factors for positive temporal artery biopsy. Semin Arthritis Rheum 2001;30:249-56.
21. Gonzalez-Gay MA. Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions. Semin Arthritis Rheum 2004;33:289-93.
22. González-Gay MA, García-Porrúa C, Vázquez-Caruncho M. Polymyalgia rheumatica in biopsy proven giant cell arteritis does not constitute a different subset but differs from isolated polymyalgia rheumatica. J Rheumatol 1998;25:1750-5. Erratum in: J Rheumatol 1998;25:2483.
23. Gonzalez-Gay MA, Barros S, Lopez-Diaz MJ, Garcia-Porrua C, Sanchez-Andrade A, Llorca J. Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine (Baltimore) 2005;84:269-76.
24. Gonzalez-Gay MA, Pineiro A, Gomez-Gigirey A, Garcia-Porrua C, Pego-Reigosa R, Dierssen-Sotos T, et al. Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine (Baltimore) 2004;83:342-7.
25. Gonzalez-Gay MA, Lopez-Diaz MJ, Barros S, Garcia-Porrua C, Sanchez-Andrade A, Paz-Carreira J, et al. Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients. Medicine (Baltimore) 2005;84:277-90.
26. Orozco G, Alizadeh BZ, Delgado-Vega AM, González-Gay MA, Balsa A, Pascual-Salcedo D, et al. Association of STAT4 with rheumatoid arthritis: A replication study in three European populations. Arthritis Rheum 2008;58:1974-80.
27. Palomino-Morales R, Vazquez-Rodriguez TR, Morado IC, Castañeda S, Ortego-Centeno N, Miranda-Filloy JA, et al. Lack of association between STAT4 gene polymorphism and biopsy-proven giant cell arteritis. J Rheumatol 2009;36:1021-5.
28. Palomino-Morales RJ, Rojas-Villarraga A, González CI, Ramírez G, Anaya JM, Martín J. STAT4 but not TRAF1/C5 variants influence the risk of developing rheumatoid arthritis and systemic lupus erythematosus in Colombians. Genes Immun 2008;9:379-82.